Section Arrow
Quote
APLS.NASDAQ
- Apellis Pharmaceuticals
Quotes are at least 15-min delayed:2026/03/20 00:23 EDT
Regular Hours
Last
 17.97
+0.08 (+0.45%)
Day High 
18.01 
Prev. Close
17.89 
1-M High
22.81 
Volume 
2.35M 
Bid
17.45
Ask
18.2
Day Low
17.57 
Open
17.89 
1-M Low
17.435 
Market Cap 
2.29B 
Currency 美元 
P/E 98.44 
%Yield -- 
10-SMA 19.21 
20-SMA 20.33 
50-SMA 21.68 
52-W High 30.48 
52-W Low 16.1 
Exchange NASDAQ 
Valuation Estimation
EPS (Current/Estimated)
0.18/-0.69
Enterprise Value
2.66B
Balance Sheet
Book Value Per Share
2.90
Cash Flow
Cash Flow Yield
0.02
Income Statement
Total Revenue
1.00B
Operating Revenue Per Share
2.13
Industry Comparison
More
Code Name   Last Change Change (%) P/E P/E Range
SERSerina Therapeutics2.48+1.2+93.75%-- 
AZTRAzitra0.1761+0.0394+28.82%-- 
HUMAHumacyte0.8541-0.2059-19.42%-- 
GERNGeron Corp1.55------ 
IBRXImmunityBio8.82+0.26+3.04%-- 
Industry overview quotes are at least 15 minutes delayed (Except Overnight Trading Session)
Business Description
Apellis Pharmaceuticals Inc is a commercial-stage biopharmaceutical company focused on the discovery, development, and commercialization of novel therapeutic compounds to treat diseases with high unmet needs through the inhibition of the complement system, which is an integral component of the immune system, at the level of C3, the central protein in the complement cascade. Currently it has two marketed drugs that target C3, the central protein in the complement cascade: SYFOVRE (pegcetacoplan injection) and EMPAVELI (pegcetacoplan).
Information provided by: etnet
Terms and Conditions
Bank of China (Hong Kong) Limited
Disclaimer:
This information is provided by ET Net Limited ("ET Net") and/or its third party information providers (the "Sources") and is strictly for reference only. It is not intended to provide any financial or professional advice and any person should not rely upon the same as such. You should obtain relevant and specific professional advice before making any investment decision. Before making an investment decision, you should consider, with the assistance of your professional securities adviser, whether the information is appropriate in light of your particular investment needs, objectives and financial circumstances. ET Net and the Sources endeavor to ensure the accuracy and reliability of the information provided. Notwithstanding the aforesaid, ET Net, the Sources and Bank of China (Hong Kong) Limited do not guarantee or make any representation, warranty or undertaking as to the accuracy, reliability, completeness or timeliness of this information, and accept no responsibility or liability whatsoever (whether in tort or contract or otherwise) for any loss or damage howsoever arising from or in reliance upon the whole or any part of such information.